Direct-to-Patient Clinical Trials: One Small Step or a Giant Leap?

被引：0

作者：

Desai, Aakash ^{[1
]}

Subbiah, Vivek ^{[2
,3
,4
,5
]}

机构：

[1] Mayo Clin, Div Med Oncol, Rochester, MN USA

[2] Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Div Canc Med, Houston, TX USA

[3] Univ Texas MD Anderson Canc Ctr, Div Pediat, Houston, TX USA

[4] Univ Texas MD Anderson Canc Ctr, MD Anderson Canc Network, Houston, TX USA

[5] UT MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Div Canc Med, 455 Unit,1515 Holcombe Blvd, Houston, TX 77030 USA

来源：

CLINICAL CANCER RESEARCH | 2023年 / 29卷 / 13期

关键词：

D O I：

10.1158/1078-0432.CCR-23-0746

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Genome driven precision oncology has transformed the land-scape of multiple cancers. However, access barriers exist. A recent study exemplified a direct-to-patient outreach program via social media through the implementation of a global program that offered free tumor genomic testing with a focus on rare cancers. See related article by Doe-Tetteh et al., p. 2445

引用

页码：2339 / 2341

页数：3

共 16 条

[11] Think Globally, Act Locally: Globalizing Precision Oncology [J].